Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2024-06-28 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司十届六次董事会决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement from the board of directors of 哈药集团股份有限公司 regarding a change in senior management, specifically the appointment of a new financial officer and the resignation of the previous one. It includes details about the board meeting, voting results, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The content clearly fits the category of Board/Management Information (MANG) as it announces changes in senior management positions.
2024-06-28 Chinese
哈药集团股份有限公司关于2021年股票期权与限制性股票激励计划中部分限制性股票回购注销实施公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the repurchase and cancellation of restricted shares under a 2021 stock option and restricted stock incentive plan. It details the number of shares repurchased and cancelled, the reasons for the repurchase, the decision-making process, and the impact on the company's share capital structure. The document includes references to board meetings, shareholder authorizations, and legal opinions confirming compliance with regulations. It is a formal disclosure of a corporate action related to share capital changes, specifically the repurchase and cancellation of shares. The document length is 3847 characters, which is relatively short and focused on a specific corporate action rather than a full financial report or detailed management discussion. This fits the category of a Share Issue/Capital Change announcement, as it concerns changes in the company's share capital due to repurchase and cancellation of restricted shares. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2024-06-27 Chinese
北京市天元律师事务所上海分所关于哈药集团股份有限公司2021年股票期权与限制性股票激励计划回购注销部分限制性股票相关事宜的法律意见
Regulatory Filings
2024-06-27 Chinese
上海市海华同泰（哈尔滨律师事务所）关于哈药集团股份有限公司2023年年度股东大会之法律意见书
Regulatory Filings
2024-06-07 Chinese
哈药集团股份有限公司关于所属企业药品通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding the approval of a pharmaceutical product (复方磺胺甲噁唑片) passing the generic drug consistency evaluation by the National Medical Products Administration. It details the drug's specifications, regulatory approval, market data, and potential impact on the company. The document is relatively short (1537 characters) and serves as a formal public announcement about regulatory approval and business impact rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it does not mention the release or availability of a report. It is also not a regulatory certification or insider dealing. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval and business impact that does not fit other specific categories.
2024-06-07 Chinese
哈药集团股份有限公司2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2023 Annual General Meeting Resolution Announcement" for 哈药集团股份有限公司. It details the date and location of the AGM, attendance of shareholders and board members, and the voting results on various proposals including the 2023 annual report, financial budget, profit distribution, and other corporate matters. The document primarily reports the official voting results and resolutions passed at the AGM. It does not contain the full annual report or detailed financial statements but rather the outcomes of the shareholder meeting. The presence of detailed voting results and resolutions indicates this is a Declaration of Voting Results & Voting Rights Announcement (DVA). The document length is about 4569 characters, which is consistent with a detailed voting results announcement rather than the full annual report or other filings.
2024-06-07 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.